Canis ISSN: 2398-2942

Zonisamide

Contributor(s): Laurent Garosi, Vetstream Ltd

Introduction

Name

  • IUPAC.

Class of drug

  • Anticonvulsant - sulfonamide.

Description

Chemical name

  • 1,2-benzisoxazole-3-methanesulfonamide.

Molecular formula

 

  • C8H8N2O3

Molecular weight

  • 212.2.

Physical properties

  • White/ cream powder.

Storage requirements

  • Store in tightly closed container at room temperature away from heat and direct sunlight.

Uses

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Indications

  • Adjunct therapy for canine seizures refractory to standard medication.

Administration

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Pharmacokinetics

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Precautions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Interactions

with other drugs

Adverse Reactions

This article is available in full to registered subscribers

Sign up now to purchase a 30 day trial, or Login

Further Reading

Publications

Refereed papers

  • Recent references from PubMed and VetMedResource.
  • Klopmann T, Rambeck B, Tipold A (2007) Prospective study of zonisamide therapy for refractory idiopathic epilepsy in dogs. JSAP 48.
  • Budsberg S C (2004) Zonisamide therapy for refractory idiopathic epilepsy in dogs. J Am Anim Hosp Assoc 40, 285-291.
  • Dewey CW, Guiliano R, Boothe D M, Berg J M, Kortz G D, Joseph R J, Budsberg S C (2004) Zonisamide therapy for refractory idiopathic epilepsy in dogs. J Am Animal Hosp Assoc40, 285-291 PubMed.
  • Hamada K, Song H K, Ishida S, Yagi K, Seino M (2001) Contrasting effects of zonisamide and acetazolamide on amygdaloid kindling rats. Epilepsia 42, 1379-1386.
  • Okada M, Kaneko S, Hirano T (1995) Effects of zonisamide on dopaminergic system. Epilepsy Research 22, 193-205.
  • Kaneko S, Okada M, Hirano T (1993) Carbamazepine and zonisamide increase extracellular dopamine and serotonin levels in vivo, and carbamazepine does not antagonize adenosine effect in vitro: mechanisms of blockade of seizure spread. Jap J Psych Neurol 47, 371-373.
  • Walker R M, DiFonzo C J, Barsoum N J, Smith G S, Macallum G E (1988) Chronic toxicity of the anticonvulsant zonisamide in beagle dogs. Fundamental and applied Toxicology 11, 333-342.
  • Matsumoto K, Miyazaki H, Fujii T, Kagemoto A, Maeda T, Hashimoto, M (1983) Absorption, distribution and excretion of 3-(sulfamoyl[14C]methyl)-1,2-benziosoxazole (AD-810) in rats, dogs and monkeys and of AD-810 in men. Drug Research 33, 961-968.

Other sources of information

  • Boothe D M, Perkins J, Dewey C (2005) Clinical pharmacokinetics and safety of the anticonvulsant zonisamide in healthy dogs following single and multiple dosing. Proceedings of the 23rd ACVIM Forum, Baltimore, USA. p 858.
  • MacDonald R L (2002) Zonisamide. In: Antiepileptic drugs, 5th edn. Eds R.H. Levy, R.H. Mattson, B.S. Meldrum, E. Perucca. Lippincott Williams and Wilkens, Philadelphia. pp 867-898.
  • Saito M, Orito K, Takikawa S, Kageyama T, Muto M (2005) Pharmacokinetics of zonisamide administered alone and in combination with phenobarbital in dogs. Proceedings of the 23rd ACVIM Forum, Baltimore, USA. pp 858-859.

ADDED